Licensing Potential OncoTEX's TEX Core platform aims to overcome platinum resistance with OxaliTEX as the first clinical candidate, creating licensing and co development opportunities for big pharma and biotech to broaden oncology indications beyond platinum resistance.

Outsourcing Needs With a small team of under ten employees, OncoTEX likely relies on external CROs, CMOs, and regulatory consultants; this signals clear sales opportunities for trial management, manufacturing scale up, regulatory affairs, data services, and outside R and D support.

Network Leverage As a member of The iQ Group Global portfolio, OncoTEX may have access to a broader oncology network and potential trial sites, investors, and strategic partners, enabling accelerated introductions and collaboration agreements.

Early Stage Traction Current revenue in the low millions alongside a focused pipeline suggests a balance of risk with potential for milestone driven partnerships, co development deals, or equity investments with oncology focused funds and corporate venture units.

Clinical Focus OxaliTEX targets platinum resistant ovarian cancer, a high need area; sales opportunities exist with gynecologic oncology centers, academic collaborations, patient advocacy groups, and trial networks seeking novel mechanisms to overcome resistance.